American society of clinical oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes

Journal of Clinical Oncology

Volumn 32, Issue 12, 2014, Pages 1277-1280

  Ellis, Lee M ^a   Bernstein, David S ^b   Voest, Emile E ^c   Berlin, Jordan D ^d   Sargent, Daniel ^e   Cortazar, Patricia ^f   Garrett Mayer, Elizabeth ^g   Herbst, Roy S ^h   Lilenbaum, Rogerio C ^h   Sima, Camelia ⁱ   Venook, Alan P ^j   Gonen, Mithat ⁱ   Schilsky, Richard L ^b   Meropol, Neal J ^k   Schnipper, Lowell E ^l  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d VANDERBILT INGRAM CANCER CENTER   (United States)

^e MAYO CLINIC   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^h YALE CANCER CENTER   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k CASE WESTERN RESERVE UNIVERSITY   (United States)

^l BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; HUMAN; MEDICAL SOCIETY; ONCOLOGY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY AND SPECIFICITY; ORGANIZATION AND MANAGEMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); STANDARD; TREATMENT OUTCOME; UNITED STATES;

CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; MEDICAL ONCOLOGY; SOCIETIES, MEDICAL; TREATMENT OUTCOME; UNITED STATES;

EID: 84899911233     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.8009     Document Type: Article

References (27)

1. Tang JY, Mackay-Wiggan JM, Aszterbaum M, et al: Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med 366:2180-2188, 2012
2. Von Hoff DD, LoRusso PM, Rudin CM, et al: Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 361:1164-1172, 2009
3. Kwak EL, Bang YJ, Camidge DR, et al: Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703, 2010
4. Chapman PB, Hauschild A, Robert C, et al: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516, 2011
5. Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819, 2010
6. Vogelstein B, Papadopoulos N, Velculescu VE, et al: Cancer genome landscapes. Science 339:1546-1558, 2013
7. Hodi FS, O'Day SJ, McDermott DF, et al: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723, 2010
8. Verma S, Miles D, Gianni L, et al: Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 367:1783-1791, 2012
9. Meropol NJ, Kris MG, Winer EP: The American Society of Clinical Oncology's blueprint for transforming clinical and translational cancer research. J Clin Oncol 30:690-691, 2012
10. Maitland ML, Hudoba C, Snider KL, et al: Analysis of the yield of phase II combination therapy trials in medical oncology. Clin Cancer Res 16:5296-5302, 2010
11. Sharma MR, Schilsky RL: Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol 9:208-214, 2011
12. National Cancer Institute: FDA approval for crizotinib. http://www.cancer.gov/cancertopics/druginfo/fdacrizotinib
13. Hayes DF, Allen J, Compton C, et al: Breaking a vicious cycle. Sci Transl Med 5:196cm6, 2013
14. Diaz LA Jr, Williams RT, Wu J, et al: The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 486:537-540, 2012
15. Blumenthal GM, Scher NS, Cortazar P, et al: First FDA approval of dual anti-HER2 regimen: Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer. Clin Cancer Res 19:4911-4916, 2013
16. Casak SJ, Lemery SJ, Shen YL, et al: U.S. Food and Drug Administration approval: Rituximab in combination with fludarabine and cyclophosphamide for the treatment of patients with chronic lymphocytic leukemia. Oncologist 16:97-104, 2011
17. Thornton K, Kim G, Maher VE, et al: Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res 18:3722-3730, 2012
18. Deisseroth A, Kaminskas E, Grillo J, et al: U.S. Food and Drug Administration approval: Ruxolitinib for the treatment of patients with intermediate and high-risk myelofibrosis. Clin Cancer Res 18:3212-3217, 2012
19. Conroy T, Desseigne F, Ychou M, et al: FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825, 2011
20. Kindler HL, Ioka T, Richel DJ, et al: Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: A double-blind randomised phase 3 study. Lancet Oncol 12:256-262, 2011
21. Von Hoff DD, Ervin T, Arena FP, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369:1691-1703, 2013
22. Pirker R, Pereira JR, von Pawel J, et al: EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: Analysis of data from the phase 3 FLEX study. Lancet Oncol 13:33-42, 2012
23. Rossi A, Di Maio M, Chiodini P, et al: Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: The COCIS meta-analysis of individual patient data. J Clin Oncol 30:1692-1698, 2012
24. O'Shaughnessy JA, Kaufmann M, Siedentopf F, et al: Capecitabine monotherapy: Review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist 17:476-484, 2012
25. Cortazar P, Justice R, Johnson J, et al: US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol 30:1705-1711, 2012
26. Grothey A, Van Cutsem E, Sobrero A, et al: Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303-312, 2013
27. Porter ME: What is value in health care? N Engl J Med 363:2477-2481, 2010